Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel of expert faculty will dive into a case involving a patient with early TNBC and discuss the latest data and potential roles of PARP inhibitors (PARPIs) in the first CME activity offered in this TNBC series.
Educational Partner: The Academy for Continued Healthcare Learning (ACHL)
Medium: Online Presentation
Commercial Support: Support for this activity has been provided through educational grants from Gilead Sciences Inc.
Sponsored by the University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Overview
Syllabus
At the conclusion of this activity, participants will be able to:
- Discuss new targeted treatment approaches in the setting of triple-negative breast cancer;
- Assess the current evidence and treatment recommendations with the PARPIs for TNBC;
- Implement strategies to facilitate the use of novel therapies for TNBC in community-based settings.
Tags
Related Courses
-
Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?
-
TNBC Case Challenges. Test Your Treatment Skills!
-
Improving Breast Cancer Disparities: Treatment
-
Race, Ethnicity, and Breast Cancer: Health Equity Panel Equity Training
-
Improving Breast Cancer Disparities: Screening and Diagnosis
-
Expert Insights - 19th Annual International Ultmann Chicago Lymphoma Symposium
